JAZZ Jazz Pharmaceuticals plc

NASDAQ
$227.32

Jazz Pharmaceuticals plc (JAZZ) is expected to report earnings on February 1, 2027, after the market close. The consensus earnings estimate is $5.97 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.9% since its last earnings release on November 2, 2026.

Jazz Pharmaceuticals plc Beat Consensus Estimates, Raises Guidance
Monday, November 2, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 1
Monday · 4:05 PM ET
Earnings Whisper
-
vs $5.97
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $230.60

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing life-changing medicines for people with serious diseases -- often with limited or no options.

Sector

Healthcare

Industry

Biotechnology

Held By 6 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.